Cann Group has the first licence. They are a private company, and not AC8.
I dont think antitrust rules would apply here in a new market, and when considering there is an approval process for importation licences.
Canopy owns 10% of AC8 as it stands from their last disclosure. This is super valuable as they are the biggest MM company in the world so have the finances, connections, etc to make sure AC8 is a success. In saying that I just cashed out of AC8 this morning as IMO it is way overvalued at the moment, ill get back in once it all settles.
MXC is in a good position, being Israeli backed (we can sell there too now if we get the local licences) and that we have an indoor facility, outdoor facility, derma range and trials coming up. Not to mention Dr Ross and many other connections locally within govt and academia. There is a lot going on and I think MXC, despite having its fingers in a lot of pies, is well poised for a long term play, and thats the way ive always treated it.
IMO, DYOR, etc.
MXC Price at posting:
7.5¢ Sentiment: Buy Disclosure: Held
